|
cervical cancer
|
0.310 |
Biomarker
|
disease |
BEFREE |
PIAS3 responsiveness may reflect greater resveratrol sensitivity and improved therapeutic outcome in CCs.
|
26432044 |
2015 |
|
cervical cancer
|
0.310 |
Biomarker
|
disease |
CTD_human |
Biological significance and therapeutic implication of resveratrol-inhibited Wnt, Notch and STAT3 signaling in cervical cancer cells.
|
25061499 |
2014 |
|
Uterine Cervical Neoplasm
|
0.300 |
Biomarker
|
disease |
CTD_human |
Biological significance and therapeutic implication of resveratrol-inhibited Wnt, Notch and STAT3 signaling in cervical cancer cells.
|
25061499 |
2014 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Furthermore, upregulation of PIAS3 by intracolonic administration of PIAS3 lentivirus or anti-miR-18a lentivirus in AOM-DSS-induced mice led to dramatically reduced tumor sizes/numbers, whereas knockdown of PIAS3 in CAC mice significantly promoted tumor growth.
|
29896300 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our findings indicate that the pathway of miR-199a-5p targeting both PIAS3 and p27 is a possible mechanism that contributes to tumour growth in OS.
|
28120918 |
2017 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
PIAS3 protein expression is decreased in a majority of lung SCC tumors and cell lines.
|
25573684 |
2015 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
PIAS3 expression in human mesothelioma tumors is significantly correlated with overall survival intervals (P = 0.058).
|
25124686 |
2014 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The negative correlation between STAT5B and PIAS3 (rho = -0.43) was also observed in T2a+T2b tumor group.
|
25137041 |
2014 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Thus, we conclude that the <i>STAT3</i> pathway plays a role in the development and progression of HGSC from its earliest premalignant states.<b>Significance:</b> Concomitant gain of pSTAT3 Tyr705 and loss of PIAS3 appear critical for initiation and development of high-grade serous carcinoma.<i>Cancer Res; 78(7); 1739-50.©2018 AACR</i>.
|
29339537 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Thus, we conclude that the <i>STAT3</i> pathway plays a role in the development and progression of HGSC from its earliest premalignant states.<b>Significance:</b> Concomitant gain of pSTAT3 Tyr705 and loss of PIAS3 appear critical for initiation and development of high-grade serous carcinoma.<i>Cancer Res; 78(7); 1739-50.©2018 AACR</i>.
|
29339537 |
2018 |
|
Squamous cell carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
SHP2, PIAS3, and SOCS3 are STAT3 negative regulators; therefore, their statuses in cervical adenocarcinoma (HeLa) and squamous cell carcinoma (SiHa and C33A) cell lines without and with resveratrol treatment and their correlation with STAT3 activation in CC specimens were investigated.
|
26432044 |
2015 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
These results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy.Clin Cancer Res; 20(19); 5124-32.©2014 AACR.
|
25124686 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The aim of the present study was to evaluate the relationship between STAT5A/B, COX-2, and PIAS3 mRNA expression and tumor staging, metastasis status, and histopathological subtype in 71 patients with confirmed non-small cell lung cancer (NSCLC) diagnosis.
|
25137041 |
2014 |
|
Squamous cell carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Protein inhibitor of activated signal transducer and activator of transcription 3 (STAT3) (PIAS3) is an endogenous inhibitor of STAT3 that negatively regulates STAT3 transcriptional activity and cell growth and demonstrates limited expression in the majority of human squamous cell carcinomas of the lung.
|
23959540 |
2014 |
|
Malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
Thus, PIAS3 may represent a promising lung cancer therapeutic target because of its p53-independent efficacy and its potential to synergize with Bcl-2 targeted inhibitors.
|
23959540 |
2014 |
|
Carcinoma of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
Thus, PIAS3 may represent a promising lung cancer therapeutic target because of its p53-independent efficacy and its potential to synergize with Bcl-2 targeted inhibitors.
|
23959540 |
2014 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
These results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy.Clin Cancer Res; 20(19); 5124-32.©2014 AACR.
|
25124686 |
2014 |
|
Primary malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
Thus, PIAS3 may represent a promising lung cancer therapeutic target because of its p53-independent efficacy and its potential to synergize with Bcl-2 targeted inhibitors.
|
23959540 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We now investigate PIAS3 expression in both non-small cell lung cancer (NSCLC) cell lines and human resected NSCLC specimens.
|
21497567 |
2011 |
|
Squamous cell carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
High PIAS3 expression generally correlates with decreased phosphorylated STAT3 in both SCC cell lines and human specimens compatible with the negative regulatory effect of this protein on STAT3 signaling.
|
21497567 |
2011 |
|
Malignant neoplasm of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Exposure of lung cancer cells to 5-azacytidine and trichostatin A results in a significant increase in PIAS3 mRNA and protein expression.
|
21497567 |
2011 |
|
Carcinoma of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Exposure of lung cancer cells to 5-azacytidine and trichostatin A results in a significant increase in PIAS3 mRNA and protein expression.
|
21497567 |
2011 |
|
Primary malignant neoplasm of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Exposure of lung cancer cells to 5-azacytidine and trichostatin A results in a significant increase in PIAS3 mRNA and protein expression.
|
21497567 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated for the first time the role of PIAS3 in modulating oncogenic EGFR-STAT3 signaling pathway in lung cancer and the anti-proliferative effect of using PIAS3 in conjunction with EGFR blockade in NSCLC.
|
19569236 |
2009 |
|
Malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated for the first time the role of PIAS3 in modulating oncogenic EGFR-STAT3 signaling pathway in lung cancer and the anti-proliferative effect of using PIAS3 in conjunction with EGFR blockade in NSCLC.
|
19569236 |
2009 |